VCANBIO CELL & GENE ENGINEERING CORP., LTD

Andere talen Vcanbio Cell & Gene Engineering Corp., Ltd

Aandelen

600645

CNE000000545

slotkoers Shanghai S.E. Andere beurzen 00:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
16,45 ^CNY	+0,73%		+6,68%	-18,85%

25/04	Vcanbio Cell & Gene Engineering Corp., Ltd rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
25/04	Vcanbio Cell & Gene Engineering Corp., Ltd rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	25/04
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04
Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024.	20/04
Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback announced on February 19, 2024, has closed with 6,181,212 shares, representing 1.32% for CLP 100 million.	18/04
Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024.	02/04
Vcanbio Cell & Gene Engineering Corp., Ltd announces an Equity Buyback for CLP 200 million worth of its shares.	19/02
Vcanbio Cell & Gene Engineering Corp., Ltd authorizes a Buyback Plan	17/02
Shanghai Vcanbio Jisheng Cell Technology Co., Ltd. announced that it has received CNY 20 million in funding from Vcanbio Cell & Gene Engineering Corp., Ltd	26/12
Shanghai Vcanbio Jisheng Cell Technology Co., Ltd. announced that it expects to receive CNY 20 million in funding from Vcanbio Cell & Gene Engineering Corp., Ltd	08/11
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	27-10-23
Vcanbio Cell & Gene Gets Greenlight to Trial COVID-19 Drug	16-10-23
Vcanbio Cell & Gene Engineering Corp., Ltd agreed to acquire additional 3% stake in Heyuan Biological Technology Co., Ltd. from Beijing Fuyuan Zhiyuan Biotechnology Partnership (Limited Partnership).	29-09-23
Vcanbio Cell & Gene Engineering Corp., Ltd(XSSC:600645) added to S&P Global BMI Index	18-09-23
MET Group signs energy supply deal with Commonwealth LNG	04-09-23
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	24-08-23
Vcanbio Cell & Gene’s Pulmonary Fibrosis Treatment Wins Orphan Drug Designation in US	14-08-23
Vcanbio Cell & Gene Unit Gets Nod to Begin Clinical Trial of Respiratory Distress Medication	08-06-23
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	25-04-23
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	25-04-23
Vcanbio Cell & Gene Engineering Wins Nod to Trial Stem Cell Therapy For Liver Cirrhosis	13-02-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Vcanbio Cell & Gene Engineering Corp., Ltd

Aandelen

600645

CNE000000545

Andere talen

Filters